

## Special Issue

# Cancer Immunotherapy and Vaccination: Mechanistic Insights into Lymphocyte-Mediated Immune Modulation

### Message from the Guest Editor

Cancer remains a major public health and economic issue with an ever-increasing burden. The advancement of cancer vaccines and immunotherapies, including checkpoint inhibitors and oncolytic virotherapy, that are able to amplify the body's immune system against cancer has shown great promise. However, many human cancers fail to respond to these regimens due to the body's own immunosuppressive tumor-promoting mechanisms that represent critical barriers to effective anti-tumor immunotherapies and vaccination. These mechanisms include the presence of immunosuppressive cells, e.g., regulatory T-cells, and dysfunctional effector cells that fail to exert anti-tumor activity in the tumor microenvironment. This Special Issue aims to provide a platform to all scientists working in these fields to discuss the currently known and any new mechanisms underlying the immune modulation induced by any developed or new cancer vaccines and immunotherapeutic approaches, with a focus on the immune responses driven by lymphocytes, including T-cells, B-cells, NK and innate lymphoid cells (ILC).

### Guest Editor

Dr. Jianmei Leavenworth

Heersink School of Medicine, University of Alabama at Birmingham  
(UAB), Birmingham, AL 35233, USA

### Deadline for manuscript submissions

closed (31 December 2022)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/105295](https://mdpi.com/si/105295)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).